AlphAIAlphAI — Financial news for AI agents
globenewswire.comSEP 303 min read$CADL

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics (CADL) reported positive data from its phase 2 PrTK05 trial, showing durable immune activation in intermediate-risk prostate cancer patients. Aglatimagene treatment reduced recurrence risk by 41% vs. placebo. The company plans to submit a BLA in Q4 2026. Data will be presented at future scientific meetings.

Original reporting
globenewswire.com
Published Sep 30, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CADL
Bullish
high confidence
Mentioned
$CADL
Relevance
8/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$CADLBullishMed
01

Why it matters

The disclosed data provide concrete evidence of clinical benefit, supporting a BLA submission and potentially driving share price.

02

Market read

First public disclosure of Phase 3 efficacy data for CADL, a material catalyst for the stock.

03

What to watch

Potential safety signals or manufacturing scale-up challenges could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: today

Background

Candel Therapeutics (NASDAQ: CADL) focuses on multimodal immunotherapies; the aglatimagene platform is being evaluated in localized prostate cancer.

Company-level read

Ticker impact

$CADLBullishHigh confidence
Context

Candel Therapeutics disclosed Phase 3 trial results showing significant reductions in recurrence, metastasis and salvage therapy need for intermediate-risk localized prostate cancer.

Expected impact

potential upside as market prices in improved efficacy and BLA filing prospects

Evidence & confidence

Efficacy endpoints are statistically significant and support a forthcoming BLA, a material catalyst for a clinical-stage biotech.

Market effects

Sector

Strengthens the immunotherapy oncology sector and may lift peer biotech valuations.

Regional

US biotech market may see modest gains as investors reassess similar adenoviral platforms.

Global

Limited to biotech investors; no broad market impact.

Counterpoint

What could challenge this read

Skeptics may question long-term durability and regulatory hurdles despite early efficacy.

Key entities

  • Company
    Candel Therapeutics

    Clinical-stage biopharma developing aglatimagene immunotherapy.

  • Product
    Aglatimagene besadenovec

    Investigational adenoviral immunotherapy candidate.

Read at source← All news

Related articles

OCT 22
$CADLMedAI 8/10

Jefferies initiates Candel Therapeutics stock with buy rating on prostate cancer data

Jefferies initiated Candel Therapeutics (NASDAQ:CADL) with a buy rating and $25 price target, citing positive Phase III prostate cancer data. The stock trades at $8.37, with analyst targets ranging from $15 to $29. The company has a strong financial position and plans a 2026 biologics license application. Recent data showed a hazard ratio of 0.70 and 80.4% negative biopsy rate. Other analysts also reiterated buy ratings and raised price targets.

investing.com2 min
OCT 2
$CADLHighAI 8/10

H.C. Wainwright reiterates Candel Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $23 price target for Candel Therapeutics (CADL) after positive Phase 2a trial results for non-small cell lung cancer. The stock is up 88% in a year, with analysts' targets ranging from $15 to $29. The trial showed a median overall survival of 24.5 months, higher than historical benchmarks. Several analysts have recently upgraded or initiated coverage with Buy ratings and price targets between $15 and $23.

investing.com2 min
OCT 1
$CADLMedAI 9/10

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Candel Therapeutics (CADL) reported phase 2a trial results showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors. The trial involved 46 patients treated with aglatimagene besadenovec plus valacyclovir. Results were published in the Journal for ImmunoTherapy of Cancer. The company is advancing a phase 3 trial (AURORA) for this treatment.

globenewswire.com3 min
SEP 30
$CADLMedAI 8/10

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Candel Therapeutics (CADL) presented data at ASTRO 2026 showing aglatimagene besadenovec significantly increased immune response in prostate cancer patients over two years. The phase 3 trial showed 80% of aglatimagene patients had negative biopsies vs. 63% of controls. The company plans to submit a BLA based on these results.

globenewswire.com2 min